Titan teams with AllianceRx Walgreens Prime

Print Friendly, PDF & Email

Specialty pharmacy to expand patient access to Probuphine.

SOUTH SAN FRANCISCO, Calif.  — Titan Pharmaceuticals announced Thursday the execution of a specialty pharmacy distribution and services agreement with AllianceRx Walgreens Prime that will expand patient access to treatment with Probuphine (buprenorphine) implant, Titan’s unique six-month maintenance treatment for opioid use disorder (OUD) in eligible patients.

Titan expects the majority of Probuphine sales in the United States to be through the specialty pharmacy distribution model, where a specialty pharmacy such as AllianceRx Walgreens Prime carries inventory, directly handles the subsequent patients’ insurance billing and payment processes, and ships to the health care provider as prescribed. This system is designed to facilitate patient access to treatment by streamlining the product ordering and fulfillment process for healthcare providers and their staff. Titan’s strategic expansion of its network to include AllianceRx Walgreens Prime, one of the nation’s largest specialty and home delivery pharmacies, is a key component of its focused commercialization strategy for Probuphine.

“We are proud to partner with Titan to facilitate treatment access to Probuphine,” says Tracey James, vice president of pharmacy services at AllianceRx Walgreens Prime. “For many people with OUD, the most effective treatment is the combination of counseling and medication-assisted treatment, or MAT. Our pharmacists use an integrated care management program to deliver comprehensive and collaborative care for patients throughout their care journey.”

“We are excited to expand our specialty pharmacy network for Probuphine to include such a nationally-recognized leader as AllianceRx Walgreens Prime,” said Titan’s chief commercial officer, Dane Hallberg. “AllianceRx Walgreens Prime has excellent relationships with third-party payors and a network of fulfillment sites that spans the entire country. Its broad reach will significantly improve the ability of OUD patients to gain access to long-term maintenance treatment with Probuphine.”


Comments are closed.